<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>FISH tests</title>
<link rel="stylesheet" type="text/css" href="view.css" media="all">
<script type="text/javascript" src="view.js"></script>
<style>
.collapsible {
  background-color: white;
  color: black;
  cursor: pointer;
  padding: 8px;
  width: 100%;
  border: none;
  text-align: left;
  outline: none;
  font-size: 14px;
}

.active, .collapsible:hover {
  background-color: #fff2e6;
}

.content {
  padding: 0 18px;
  max-height: 0;
  overflow: hidden;
  transition: max-height 0.2s ease-out;
  background-color: #f1f1f1;
}

table, th, td {
  border: 1px solid silver;
  border-collapse: collapse;
  font-size: 10px;
}

</style>
</head>
<body>


<div>

<img id="top" src="top.png" alt="">
<div id="form_container">
	<div class="form_description">
		<h2 align="center">
		<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAGAAAABgCAYAAADimHc4AAAABmJLR0QA/wD/AP+gvaeTAAAe5klEQVR4nO19ebgdR3Xn75yq7nvfKsnad1kS3mSDTQwEs8SQEAuIxfaZMCYEw8cyw/KFbSCOIaOBWIbBhsQGzwCBMHEIjs0yAWwgTCIDZhkMGOx4ixfZwpaftT/pLfd2VZ0zf1R133vfIuk9vYdIvnfk/m7fft23q86pOud3lioDczRHczRHczRHczRHczRHczRH/87prr/edNKJbsNUiE90A8bSfVdteso9Hz3lquk8e+9HTu3jg+HHM92m2aTfOAEI3NOd92+89SOn9k31WZPbrRJkgypoNto2G/QbJwCInqKKvsVW3zWVx+6/+pzFzrs3KYEfuOacRbPVvJmm3zgBBMXJAOBceJNuPd8e84O+cYWI9kIVBcuSWWvgDNNvnABUZC1Uoaor7u977B3H8sxDV56+NgR5NROBidBdyMapvPP+zzx51b0fPf2/Tq/Fx0fHPsKmSHdcvuZ9YPvoky996AtTec4wrWCyIACi9L77rzrt9wS0hhlLRFEnoIdAHoQmEQ1DdU8g1I2YOqtAAKilU471ffd/4vSnFgcaN2WG/26qfZwJmjUBGNLdjaL52bsuX7t/02WPfPNo9+/YdsppPscbnNASaxQAgQmLwHSBAUEBGAOQAgBZAJaAHmVewgCUFQoDVkB8eM9Df3XWRhb3+XXvvPdHk73z/o9turA5VPy9QnqctZ+fqb5PhWYNLdz5odUbmkEeYKKhHpP97qnv3/GTsfc8cNWG1YXYN5OGlxLoDBCImUFEAAjMBBCBQKCqpelcO39L0zWFAhJ7JqIAsNNk+KJk9Ss2vPlng+X991x12nu889ugmrHhHZvee//62eHEkWlW4drP/vuqg6o6j4n2U55vPufSh24DgPs/tnFT0+kHGbiQiDImApVHEgAxQOU/ioIAkIQTSds6oKpRAOUFUSgAVYmfIofY0OdpWD7uMlztQrhQJP4ty8ynT3/Pv715NnkxGc2qAG7/4KqfBJGnAQRj6JA19k8N08sC8HxLbIgjg9kYAEAUBEBsQAQwKLUwXSdKA79tRrTNBEFSUaRQTcxPfxcRSLyookoighAAUYHN7ZbT33Xv12eTF5PRrNmASLRDFU+zhkDgfgKuFQUsM0AEZq6Y3DELErOjJmIQWqM/yQMEgAxDQ9I3UDAAFYWm+xQMJUBFwMwgUQiEKNoXkFVIIMl7iu/NLh8mp1mFoQw8YA2DmGAMAcQwHNWMNQQGgUyEjsw8RggcmU8AE5BkBsOAIYIxBv1rN4A4Pl+qKqL0OxwFxkmtMXF8BzNM9T4GGzOw4c0PDR69N7PGo9mhhz++drmSvpCZYJjTgcSApMs5CoErRkXDW450TmqoFAqDoBrVUDZvAchaUKn3k53givFJ2ERJ6AAxOt4TBY8VD37s9Oum5PTNIM2KAH65dfnmfYf8HUQ4J3YyMTB9zl+9GmxsJYhoC1CNYo6TJaoeUiRzCpCCSEEE2N4eaHBgw2AoiCSpJyo1UjLhqITHAOKAaLWHwRDIHz3QP3DLjo+vm3+kft195clr79x28tV3XbnxjJni1YwL4PbLV17qQV83TIsY7SOt1WlTq2HhxlNg83piDpJSL3G+gpCYrYmnmm5hQt7bB4JCnYu6HSU6is8xAEoPcCmMZE9KeEtJUFGgDFV9ltfa9yYSwl1XbNj8i8vX/FNjxD+gqk/b9J4H7p4pfk0ZBf3kA4svgfLmLMMXz9YnbqKt8OXffrF1+YeC4DJjmUpdb8gADBg2Vcfz3j4sWLMO3jk09u5BMXwooqE2SZSGuMW8ZIiZUVu4GMwGSoxi/16IK9ABShP0KRFQkikUimzefJhaHUOPP5pQUfQXRAUSAhR0h+3zz5UR3lA0w6udDy8V0fUKBYP2a637rKe+775d02X4WJqyAG6+emNt0e7B24LoWcR0yBJ/jwx9GaJPVuAdxhiK09wATDDEcRYwJ7ViYAjoW3syjDFQEbiRIfhDhyHiK5zPFMdzpxMG2J4emFp35Ru44UOQZgMAx2kirZ4l1Jk0ksL29qN7+UqMDOxC8+ABiAACgYhCRaCiCCIIqiMioVu8ICThgKA1Yy8+87KHrz9+trdoWn7A3ZcvWn5oBD9XxbLyF6wpDW0a6WxgOGJ6ZoAjLIGJUkBt3nzU++dBRYDgEUKANkYhRRGdqgjoKwGoKmAssp4eAJwcNiA0m/CjI8lwly4yJbuBNPIB29WN+pJlYDYYfPhBiPcAFF4EEIGkmaAqCBIi44MiBIGIhzHmxqe8f+crj5/lnTQtG3DGZXsfr9XsFhBGoJqMGlfIhrgctUmVaEIo6XkC4IeHIN5DnEPwDupcHPHGRHUjGjG9KqLHqiCykKaD+gLqmgiFS7+X7oNAIVCVcvgDAGxXF/IF8yHewY2OQIMD0jOxmaUdqRRgQmcAs8IYc9h2y38+Lk5PQsflCf/kA4svkSB/Y4yBMQxjGEQMYwhMJsG+Et9zhc1jZxm1/nlgY6DBI/gAhAANHloGcxRgaHSdiGNAjuM7UMaJiCFFE6IKU+oqUqhGbtpaHaanD8QMMCM0G2gc2BdnRrILEqKgREOlhlQALwKRAGa+ctOf7jimcPUj1z57QXddv8mG+7PMvKn/4ltuPdL9x4WCiHAaVYiCqh8sVUF7tCCClDKQEK+65iiCa8IXcVQH56AhABr1MbQKH0AlABIg3iH4AqFoQppNBNeI6ibNFIEiSFRhnGWAtQiugLgC4h2k2WghqlI/UdXKhIwIpYyZSMB6TDlqVVBmw/Wi+gxVPV28fOfQ3z3vWUd6ZtoC+OmHF8zzXt5aOU1o4fiKydpyqBQRp5MmXK+AOofgHMQV8K6AqkNQTbo4QGNiJsV0kiDavosKxAdIKTSVJMCIWSQIQhHVmzgHdR7BRd0vMVIHqHSoxgk+WQIuPxae/Op/nfsOUfn9st2iWlfIlwdvuGDSSo1pC0CH+G0E9JZufwwbaxu2pojFgXKuJ62SAmUIUA0IRQEJDpDWqO9kdifTO7+PvZYOEYgv4F0Tko6QDg0OogpKUdLI5AidKhtgDfKensoDh8pr79i27neOxI8Hr/mts0RwRWJ8e3uWGl98dMYF4BWviA3W9EPa8npSRNL2Lcfyl3wS695+B9a97ZdYcuG1yOafDCQjKUGgwUM6GDnxOdq/S6cgxgsr3oMgCEUB32giNIuIsIJUs1BLRwGxH6KKrKsbS04/C8ZaoHQGiQxDrp2s2uKOa89aICpfUtVa2+ivcICovrZxw/NOnTEB7Ni6rg7VTa3AWUvtlF6p6V2ONZfcjJ4nbQbnPeC8B90bXoDlr7oRtndZpQIkwcB25nUydKKRP9Hs6JwRpqu78gNEAoIrEJqNDiGiRE7pN+r989C/5mSI9xgdPIhy2hIAET3jzivWvGksL+765KberIGvqOoprZHfMvDJPpkQMKERn5YA9haDGwnIW6gbEX5W3xRLn//nMPX52L59O8477zycd955uOWWW8D1eVjwO38WDayEcXr92Jgu0XGaaOQnQfSvXgdTyzqEE4KPhlgESJAVGkMR9ZMWo+ukhdDgMbznidZggpZxPmgIH7j56o21kg8//4vT14Zh+q4qzlctE0BlcqhNGJFPF+kNz+way8tpRQBFdWMFAwGUr1ClhMkJ3Sc/FwBw2WWXYWBgoDr/wQ9+gK51z63QzVgqhdoeWig92fGoOfrKY38l7+0DrAXZDKqjY56INko0Om4my2D758NkWQxpiKBxcH/VGBWUcUBAsXLVgZF3/Gjrxu8Ya14L1jdDpaZqYle0GvOVMJCEAEX/KLo2A/hqe3umLIAbtiJHkz4UoVwbk8rTCtKNZ26LC9FQjmfsWCYf5buWLy4p/i3vXwApmgCZDj3fej2BDcHkNZCtRU8cChULGW1AnKsYR5TUYsKuTvTDgH4YKlCYcuhV97eY3hpGpTJipedgjACmrIJWFfPeHVTOpDZGUzX3Wp8jj/wAALBt2zYsW7YMy5cvx7Zt2wAAIztumVB9dBja6pqMM7odsHTM3zjLwDaDL5ogpklUVICqTx54A6FoIjiHUBQoRoZKLlaMa3FSo2+gYezobgmiYnopmNbPieLpY/k5dRUU5PVg0xrfCoC1mtol7d6+DV2rfxvnn38+fvjDH7YeHz2A3f/ywcjYSUf+WJpY/Uz0TN7bh+CbgI8qUlXG3QMAwSkoFFArIFGwKNQYhMZoCmeUjCMAEuG1AFCFoQIBWdvoHtOulvzGCEXXjG3HlGeAKtaQKqgc8aSVyLWCd4Ji3wN4+HO/h8P3fgPSPAxpHsbhe76Ohz/7ArhDuyYY/eON8JHQUGu2SBXJJGuhxPDNJnzRSBNyIkMd2yki0UtuNhBcI3nLPulyoJJCQkyVuhOfjEObiikZ3j5hxhGNq1md8gx4ZE/fX/Z2hzcs7HP1Gms3lFoGQBHhXUqOuMHH8NhXEnKrrKu2VTdMMIo15k20PGkfUdUMm2i2KExWQ2g2oupByiszR+94gvsBAEIIpKCmQGxEZhXzqU1/tD0CACQFKvaN4/ak9m/cdJyyAC7+m13v+9hFJ//q7l24uq9eYM0iJ6sXCqDKRAoox7mq1AlyqhkzvrEtJKMAGNCUSTMGxAZQTaGKlnaN1PoxNjaGNYKP6Ixj2JsMQ7wb35FOHQoJASSJP6XaSgNKtaXKykwdpADQnaKpY/s1qTrdO/bCtGDou27c8YkPbTm5+cQh86lf7Wfurnk8fX1wKxYgi8xvQ0hUDiaFlhl0VbRaHnuqoBjNTMkcNgbMBtZasLGwvf3w3qMoGiiKRswjtAlCJMTETKo1AnF0zCnNykkoir9dnUSUpKVaKcFGBTFLw1qqoVb4EWVMktrjSR3CeHTs+80UeV/R9vsO/vw5T5p30IluHm4Q7tlFZnAEWLtQPCclUqEIlTaD1IkqyvM44jNYY2FshiyzyLIsnuc1WJujXu9Cd/98LDhpMbp7+mCzGogZEjwk+GQPQrQJwUO8j98jVyfoRRt2oeprOk8jP1XPaYIxLe9awWTBNodJVRYmZf7K72UmkJnKUpgbL//Sjn9qb8FxhaP/4uadfxWAz4gqggL/+ihw/f9j60WKarSUSZUOONlpcEVjZ6zNYLIMWZbBZjXYvIY8r8NmGbI8h81rsMYCIGR5Hf3zTsLipauwat2TsHTFWmR5rROqIul0CegMV4wJ5JXJn3KIaBmqiLNMJfUDZV/KvjWlGvHU7phGiVYFZUBEZIRxuYHjEsB7tyzqU9EV1ahQ4NH9wP99cH6e9S8FTB4ZLIoyU6VSBqo6BZLlGWyWI88i0/NaHXlWQ5bnyPM6jM066kI7iVDv6sGyletgs3xy5DMpIirDEpL8DmljNlLbW2ooKi6FbzbuIeKfV+UvidGt6r4yTUIg4FD3SPjW2JZPWwX9+YVrXyHOfl1EzxUBgiqCAKtWrxi5cMvzdi9ds76/1rcUee9JMLWu2JngYmKl3QCWHqMIenvnI8vrsHkGazPYvAZj7REYP0YMxDBZhqFDB9ABxo90aCp90chWSfpIKv+hjOeU/8okPiAQ04X+s6lO5zHzOlOqm6oUJ+bJmQlk+Lraa7Z/dWybp2yEr7xo/bNtlr/f1LrPqPV0j8xftPCuVetWFCtXrbQLFi1cWO/uWkGcdZOJxrNx8Ak0h/bCDe6BG94LN3wAfmQ/3PBB+NFDENcAVFG4As3mKLp6emGshTHTK1Tr6elHltVQNBtTeErTmC4jWylIIkn3d/gkaJ81fZu23jV0xxVnvTzrxo+J6JSytL5V2woQUchAE+YEppwTfuzb7/ZsM2OzHMbm4CyDsTUwxxCAsQbEOcjYeHAGYhvxuCqaBx+HO7wHxdA+uKF98KOD8COD8I1D0MYwVq5YGisojoP273kc+/cOTOGJyDBNdUhjQ4Kl0a3qh0QhYCjnjfMuf6ILiAkZZtxmmGu2LUduDCNj/mzvq295w0RvnvIwU0gTKt2aQrpxLoaIu8HRbpGPWk/TAQAwMey7YAXqC1ZUeC00hlAM7YMfOQA3fBBh/71gf3iqzeqgendvm89wpL4gOX4KlTYjSrGsRjmDMRlgcpDJAFODmgzgdJjaASAu/tnw9p/dueOT515KRB9r6X8CEw2ErPbeydow9XmuOgJINxAhH6kBNECVQRIz2aQCaABSp1rFUu2eWPw0tS501VYDC1cDRAh7lsPd/bUpN6ud6l296Fq8HlV5Sml0SvXADCIDcHT02GRgYwG2YBuZy8ZCTQbmHGRyCFuwyYAkkCAAVB4vBQAA697y07/c9ZlnbCai308qqEGMl/e/8tv7J2vrlAVArLuhYREkAGoixGOGCsdFXOLjVA4ADGJNkCIKg9s8WC29Feq4xgtWpezH0UfwpG00GZY+4w8BCZ0zgdAqe2cDYgsyBsw2etxJGMQ2lsoEBwnRu445ZgfxBYJ3QCgAY27reC9BH7k2e5Wth28yUZ8lemP/xd+ddI0aMB0BgH6lImeoCXGUawwdQDgGqdi0roGh4tuS86b6ldZn54wgsuCexZCh3VNtWkVsLPpWnXnM92vwgLgUphao91A4IJXCQKJDR0ihbAkAApjq3x/7W2vfcusBAL99zG095lZWrdW7VWPDVDzKcyB9D8kmqIDER3MmAVCfjtA6quuh46C+pVNuVjtR14Jxvznx4QEpQJoq5SSGFVTK+iRfMR8aYpwp9RWqzXrfyDeOq6GYhgAM8ffLRqkGaIijphot6qHqkzAcRBO8k1j5VnW8Qwjt1zy4f9nxdWr+yjaBH+lIjE1ryYgoCkF86ygHlvjUt1h7RES3nnTuR457Zc2UVVBGw/9SKJzRkEEY4AAVinZAAZVUTAsCUQaQjfqcYhaKdKIyqE41xL2L25Hg1IgIZulpkblHIU0RWtLkgCkBlEGVIrCQ0DYTygHjoOJh89qN02jdOJryDDjpBZ8eNMy/KHWhlrMhFHE2hHK0OCjVQDDRwwQBMG0jvl0V+Y5ZQFkN3De9WWBXngPKu46qflR8SipRStAbKBgKjnAzpJmsrpoBsW8BBAxq4WZkZf20PB5i/bGEcoT4li2oprZEpppuSML/IANoWr8imMQetIRg1/xWhHxT6cyC1bArn1IZziMdJD4iGXUgMERjGxUGMP1R3YhrDbA2AcDg+mUXXDk8Hd6NpSmroMduet1/cqOjb2RjkuqJCEgFUGIoUbRT3A1j5wHwEAGIPQAPCs0JMlvpsw2acvd81DZthtv5c8jBx47cKCLYFU+GXflkROfwKJ1QjfeJptk6BDL9ENOflmN2QSgDpJEQUmuQBfXOOPPhqfJtMpqSAHb+4x9/cPTw0GXGGibKoRrxvyYBCLnoATKA+gooxRFMHAA3CJKRCFMJcUbQeP3fLgSq9SB/0nOgjSGEfQ9DhvZCRw7GGUYA1fvA/cthlmwE5T2oPPMOmiiZrwnFlZ68QP0AiA9D66ujI1ZfDjd6IAKJcraLA6vsWP7Cax6eCt+ORMcUC9Ltl9R3Hmj+Q1E0twCAMTF2b7PoHRqbwRgLk7JXJu8GL31+XL3Y3AVqPAqwpkUcLUcoLRgY0xRq+2hv3iTnNNHfJ+ttqf5cQm6SwuU+obkA1QzoPxOULUDz0ZsQXAPBO4TgY+lK8GCbvW/l5mv/x7Hw7qhNOtoNA195zZIR3/jnENyZSuQN2yeYea/NsoPGmNXEtN5wKQQDshb5wnPAfeuBwduBYk/yOg2ITAwDtIUCxgug7fyIQpjg+2TCIIYqI0bfXcznirSgtI8OloSYwJEQQPM2IYzsgT/8UMX44B28c/DBj9bynmeuuvBTvzwa/45GRxXAEzf/4YZmQecS0T2r+k+9m563tVoVufumS872IrcZayynVCIbg3zR2dDDO0DwMbdrTQrWlQKIhlltPTpskKS3JmjWuFzA0b63SJGMP2wUAggkTagbRoxllUdUMZLOg/cQievWxLv4GTy8d/BFmgXG7LJ2wdPWvOQTx7Vicsrh6LE0cPNrP6eirzPGRPWTWTAbMKfQtDFphaRNy5TS6DcEMnHpkCIAwYHKLHrVsmNh9gTXFNH+sAVgqvCIwkLDEMgdADSVx2sb89OCPBEP8aFifKmCvItCkFTmYmx237zuhU9f+KJrDk2Xf8e9UNuxfY+q3ysJKYhPcE0dRFw8D9ErrmCduugVUwZBYhLZlIItXX0Zg93Hfp/sWgAogNAA1MWwMTIo51C2AOWA+rQoJLZJEsSsAm9lkl8i44n423leP59zc6nN7JfI8GOAIPjmqYdG9mzX7ZfUp8u/454BADDwzT/aIi58xdjMmBRdZMspScMx2pg2yyBTzgYCuteDSKDqUtzIgZB8iYkQUkUMpeRfgABpjrmFUFZigGsIdmkShIFKARy+N4YgJC7KkxDPJXm+IgHBuzRDZFetNz9z/nP+54H2Nzx+8+vO8M5d5J3bbNj+bM3Lv/C26fBuRgQAAAPfuPgaFX2bMQacUopsOIZ3icEmqh42CQHZPlDvekAdWBwUHpAmWEdBGpesxv8SUiLbptMjgoorJwMoHG7B1xReKMthorNbg/ZsBFCLLsL+HyXVE5mvGlVQLGORluoJ3hnOL1i8+dPbZ4pPY2nG9oqo9eQfEPESxHdM4+CLOM19dO3j9QJq5wHIAcohVAPEAcU+IKR1vNJSEZAYfye2ADJoOgQZSFteb1RzyYMNLl4PDuQPA4f/DYAFTE98Z1I5LbVZxGtS5gCccsbvnk3mAzO4YdPooZFXBe8ZVXpbAdi4zhcKNgrxceMkKIPqy6Bci05xcwDqBkCI29FEih4dIUT0wh7aFEi+NCZ+YBBLCodAwUM11ZxWZc1xN6wqme4OQHEn6KRnIZj50Mb+hHoS8gkhjX4PEQEbvmrxCz53zUzxZzKaMQG4ZuMiVUHcNiYJQCW9IhpLYhuZny0E54uhfgh68E5QGExJcVOFhePeD1JFRVUYYA/2ByB2ZYzZwIBSMgVpp6yWANqrqFMd0vCjAN8OyubFtQFpgw4pHbIQSoRz6+IL/vevZR/RGbEBO266aFk4OPgIEefWGNha9gCTzZmwho1NRbatHavskufA9KxCeOI7oDCc4Gnbgu9ym7KU2IZSqvlMgYTuJwH5omgPhu4CFQcq/V8tnEBZSIW0ngwoCwlEDcQ3Kz9AyvVjoayk04Fbm7Lqla+88egx7eOkGZkBZqTxdi+SAyqmK/vUSN58Z7/rmq9SfCegOEvVwhgDEQYMQ90gip0/AVOJdmJgL/oBcVctQbtAYo45KhaCDu0AFq4AOAeFGKlEVTTbqu2PE6BNDUkqqtJm26hP3q8IQlr0LRKWPbdWuwjAjO6MMhHNiAC8a17MRIN5rev1q172ta+ky08MfPs1z6Tm6Bck+JdANe0DauD2/jQiGKYUnghg4qT/CUhJGwUBaZsxpDUFpATAASM7gf6zUlauiPdLfCqej13MoRXTS0FIWcgLHWbC33oJrwzeLRQJGJXwXvwaBHDcKOiRL295FhEGbVf/U1dfVDEfALDsguuGl2750kvJ0ntFfCMkNz+46F2Kj66+OF8tIVUJEYWUIWDv4zM+nktZqTB4N0QRr4fQ9re0FDWUjqBDCK5CY9GrdZCQ9o7QcLcx9IzFL7r+Ld3zw0Y29PfeO/HN5jk7v/SKC46XP0ej47YBuvV8S1tv8Ue7b9+3LtzkC/u3KvpUZq78gWqTPmptZYmqtC+pn9Iwj21t73pgeBc0NNLfkvopRz/GL/CLzpVCRQMRfW7RsvlvpXM/3bGC49Ebtry48M1PE5uHT37VzUfcbON4acYcsWMhVdDem176J97hz4ixmNNuWjE419rLTZE27itzBmkzLEWJkGLTVVMVZ7sBhlQ1nXFhRlI/Iel8VRDouxD7ziUvuf72ydo68O3X9DQPH/hva6TrUppFY/xrFUBJe/5xS18QvQ/AclBrFkRvuaxeS4VaaSOQCE9jkyfK15cJ9gr9VEIod1ZRgPRBJvsni//gxpt+zV2elE6IAADg0RtfOABgKRsjxvD9qnoql5sxAW1qCUkFcRWZbk9oti8jqlBPWdncjn5UYa396yVbvvrGX3NXj0gn7H/gEJzrCc4BwGeXvuRrp9XqejZUPyEh3B28C9FYR6MZY/MOvjKg8QhtBjZ4l+4P0BAOQPWbrPoWFfmuT0bcNZurTlR/J6MTslusKuiB61x3ZrMHh+vh7QCwYPM3fgng7QBw6OsXLhr12EyWzg5BTyeE1USYL6onQdGTVJGo6G4yvI9BuwG6nzPc6TX77uIX33hn+a4D21/6xeIJuT0Etw5sVpyI/h6JTogK2v+di+bte3z37lpP17PXvOJbtx39iUh7//milc0DQzuhymzN95e/7KbnHstzA9948ZlD+4d/SKDhDX+8ffn0Wz7zdEJU0D431Kh31d86FeYDwKLfvfExFdznfQAYtxzrc8v+4KZ/rfd0vV5VF+i/o//F1W8k/eqGC6556Lrn6cD/edEzpvrszhte+F9O1Cbd/2HokS+/8FkPXnf+/rmRfAJp5z+8aFY2UZ2jOZqjOZqjOZqjOZqjOZqjOZqjOZqjOfoPTv8fAZm+1drewYsAAAAASUVORK5CYII="/>
		<img src="data:image/png;base64,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">
			<br>
			FISH tests
		</h2>
	</div>
<p align="center">This is the list of FISH tests available in the laboratory. <br><br>
<p>Click on the gene name for general information of the probe and its respective common applications. Web-links to the manufacturers' websites and genomic maps of each of the loci are provided. <br><br></p>
<p align="center">Please note that only ALK breakapart FISH and ROS1 breakapart FISH are accrediated tests.<br><br>
Please order the test through the desktop little fox.<br>
</p>
<br>
<p>
FISH is performed on formalin-fixed paraffin embedded tissue sections. Composed-pseudocoloured images are captured for enumeration. Pathologists might count at least 50 interphase tumor nuclei. Positive cut-off for FISH tests varies on the nature of probes, specific genomic changes and in different diseases. As low as 15% has been proposed in published guidelines for some probes e.g. some types of BRAF translocation in pilocytic astrocytoma, RET translocations in non small cell lung carcinomas, etc.
</p>
<p>
References databases:<br>
1. <a href="http://atlasgeneticsoncology.org/" target="_blank">Atlas of Genetics and Cytogenetics in Oncology and Haematology</a><br>
2. <a href="https://cancer.sanger.ac.uk/cosmic/fusion" target="_blank">Catalogue of Somatic Mutations in Cancer COSMIC</a><br>
</p>

<!--
<p align="center">
<img onsrc="data:image/png;base64,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">
</p>-->
<p>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
<img src="data:image/png;base64,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"/>
</p>
<div class= "ex1">
<button class="collapsible">1p19q co-deletion (<a href="https://www.molecular.abbott/us/en/chromosome/19" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
For glioma.
</p>
<p>
Vysis LSI 1p36 SpectrumOrange/1q25 SpectrumGreen Probes and Vysis LSI 19q13 SpectrumOrange/19p13 SpectrumGreen Probes (ASR) is used in 2 separated FISH tests. Deletions affecting the short arm of chromosome 1 (1p36) and the long arm of chromosome 19 (19q13) are frequently found in human gliomas and are associated with a better survival. Determination of 1p and 19q status may aid in therapeutic decisions and predict outcome in patients with anaplastic oligodendrogliomas.
</p>
<p>
Please use Ronnie's template for scoring of a total 200 tumor nuclei. 
</p>
<p>
<img src=".\cap\LSI-1p36-SO_435kb_probemap_mw004.png" alt="1p36" width="600">
<img src=".\cap\LSI-1q25-SGn_618kb_probemap_mw004.png" alt="1p36" width="600">
</p>
<p>
<img src=".\cap\LSI-19q13-SO_380kb_probemap_mw004.png" alt="1p36" width="600">
<img src=".\cap\LSI-19p13-SGn_502kb_probemap_mw002.png" alt="1p36" width="600">
</p>
</div>

<button class="collapsible">ALK (ALK receptor tyrosine kinase) translocation  (<a href="https://www.molecular.abbott/us/en/products/oncology/vysis-alk-break-apart-fish-probe-kit" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
For Non-small cell lung carcinoma (CAP accredited test).
</p>
<p>
The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) patients. See also "IASLC Atlas of ALK adn ROS1 testing in lung cancer 2e".<br><br>
Orange Probe: Telomere side, 3' end of the ALK gene.<br>
Green Probe: Centromere side, 5' end of the ALK gene.
</p>
<p>
<img src=".\cap\ALK-BA-FISH-pattern.png" alt="IASLC Atlas of ALK adn ROS1 testing in lung cancer 2e" width="300">
</p>
<p>
<img src=".\cap\LSI-ALK-SO_300kb_LSI-ALK-SGn_442kb_probemap_mw002-kit.png" alt="ALK" width="600">
</p>
</div>

<button class="collapsible">BCL2 (BCL2 apoptosis regulator) translocation  (<a href="https://www.molecular.abbott/int/en/chromosome/18" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
For B-cell lymphoma, follicular lymphoma.
</p>
<p>
Vysis LSI BCL2 Break Apart FISH Probe kit is designed to detect translocations involving the chromosomal region 18q21.33 harboring the BCL2 gene. Translocations involving the BCL2 gene are commonly identified in B-cell lymphomas, e.g. 80% of follicular lymphoma.
</p>
<p>
<img src=".\cap\BCL2partners.jpg" alt="BCL2 partners" width="600">
<br>
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\LSI-BCL2-SGn_855kb_LSI-BCL2-SO_608kb_probemap_mw001-orange.png" alt="BCL2" width="600">
</p>
</div>

<button class="collapsible">BCL6 (BCL6 transcription repressor) translocation  (<a href="https://www.molecularcatalog.abbott/us/en/Vysis-LSI-BCL6-Dual-Color-Break-Apart-Rearrangement-Probe" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
For double hit, triple hit diffuse large B-cell lymphoma.
</p>
<p>
Vysis LSI BCL6 (ABR) Dual Color Break Apart DNA probe hybridizes to the band 3q27. The 5’ BCL6 SpectrumOrange probe is ~349 kb in size and flanks the ABR of BCL6. The 3’ BCL6 SpectrumGreen probe is approximately 816kb in size and flanks the MBR region of BCL6. There is an approximate 265 kb gap between the two probes. In interphase nuclei of normal cells, the probe generally appears as two distinct signals (orange and green adjacent, or fused yellow). Probe signals may also appear diffuse or split in interphase nuclei, depending upon the condensation of the DNA.
</p>
<p>
In high-grade B-cell lymphomas, the presence of MYC aberrations identifies a patient subset with a very poor prognosis, particularly when there is concomitant rearrangement of BCL2 or BCL6, a condition referred to as "double hit” DLBCL. In rare cases translocation involves MYC, BCL2 and BCL6, so called “triple hit”. 
</p>
<p>
<img src=".\cap\BCL6partners.jpg" alt="BCL6 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\Vysis-LSI-BCL6-(ABR)-Dual-Color-Break-Apart-Rearrangement-Probe_ProbeMap.jpg" alt="BCL6" width="600">
</p>
</div>

<button class="collapsible">BCOR (BCL6 corepressor) translocation (<a href="https://empiregenomics.com/fish-probes/gene/BCOR/break-apart" target="_blank">Empire Genomics</a> and propriety, China)</button>
<div class="content">
<p>
for Ewing sarcoma-like small blue round cell tumors, endometrial stromal sarcoma.
</p>
<p>
Empire Genomics’ BCOR Break Apart FISH Probe is designed to flank the BCOR gene and is typically used for detecting BCOR rearrangements such as translocations in small blue round cell tumors, Ewing sarcoma-like tumors that are negative for EWSR1 translocations.
</p>
<p>
Chromosome: CHRX: 39910498-40036582</p>
<p>
Locus: Xp11.4
</p>
<p>
BCOR (Xp11.4) / CCNB3 (Xp11.22)<br>
BCOR (Xp11.4) / CHCHD7 (8q12.1)<br>
BCOR (Xp11.4) / L3MBTL2 (22q13.2)<br>
BCOR (Xp11.4) / MAML3 (4q31)<br>
BCOR (Xp11.4) / POM121L12 (7p12.1)<br>
BCOR (Xp11.4) / RARA (17q21.2)<br>
EP300 (22q13.2) / BCOR (Xp11.4)<br>
ZC3H7B (22q13.2) / BCOR (Xp11.4)<br>
</p>
<p>
<img src=".\cap\BCOR-BA_GROR.png" alt="BCOR" width="600">
</p>
</div>
	
<button class="collapsible">BRAF (B-Raf proto-oncogene, serine/threonine kinase) amplification (<a href=".\cap\BRAF-CEN7.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for brain tumomr typing.
</p>
<p>
The ZytoLight ® SPEC BRAF/CEN 7 Dual Color Probe is designed for the detection of amplifications involving the chromosomal region 7q34 harboring the BRAF gene. Activating mutations in BRAF are found in many tumor types, including malignant melanoma, thyroid, colorectal, and ovarian carcinomas, lung adenocarcinoma, as well as in some sarcomas and gliomas.
</p>
<p>
BRAF/CEN7 amplification probe might also be used to look for KIAA-BRAF translocation in pilocystic astrocytoma, consisting of complex duplication and translocation events. RT-PCR assay might, sometimes, be more efficient in detecting this particular translocation.
</p>
<p>
<img src=".\cap\BRAF-CEN7.png" alt="BRAF amplification" width="450">
</p>
</div>

<button class="collapsible">BRAF (B-Raf proto-oncogene, serine/threonine kinase) translocation (<a href=".\cap\BRAF-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for brain tumomr typing.
</p>
<p>
The ZytoLight ® SPEC BRAF Dual Color Break Apart Probe is designed for the detection of rearrangements involving the chromosomal region 7q34 harboring the BRAF gene. Various BRAF translocations were observed in melanocytic nevi, pilocytic astrocytomas, malignant melanoma, prostate and gastric cancer. 
</p>
<p>
<img src=".\cap\BRAFpartners.jpg" alt="BRAF partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\BRAF-BA.png" alt="BRAF break apart" width="450">
</p>
</div>

<button class="collapsible">CDKN2A (cyclin dependent kinase inhibitor 2A) deletion (<a href=".\cap\CDKN2A-CEN9.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for brain tumor typing.
</p>
<p>
The ZytoLight ® SPEC CDKN2A/CEN 9 Dual Color Probe is designed for the detection of CDKN2A deletions frequently observed in most tumor cell lines as well as in primary human malignancies. CDKN2A gene is found in up to 80% of T-cell acute lymphoblastic leukemia cases and is associated with poor prognosis and relapse of the disease. Also, this genetic change might be important in the classification and acts as prognostic indicator for some gliomas.
</p>
<p>
for brain tumomr typing.
</p>
<p>
<img src=".\cap\CDKN2A-CEN9.png" alt="CDKN2A deletion" width="450">
</p>
</div>

<button class="collapsible">CIC (capicua transcriptional repressor) translocation (<a href=".\cap\CIC-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for Ewing sarcoma-like small blue round cell tumors.
</p>
<p>
The ZytoLight ® SPEC CIC Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 19q13.2 harboring the CIC gene. Rearrangements involving the CIC gene are frequently found in EWSR1-negative small blue round cell tumors and have been described as aggressive tumors with an inferior overall survival compared to Ewing sarcoma.
</p>
<p>
<img src=".\cap\CICpartners.jpg" alt="CIC partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\CIC-BA.png" alt="CIC break apart" width="450">
</p>
</div>

<button class="collapsible">CSF1 (colony stimulating factor 1) translocation (propriety, China)</button>
<div class="content">
<p>
for PVNS and TGCT.
</p>
<p>
CSF1, the ligand of the tyrosine kinase receptor, CSF1R, can be translocated in pigmented villonodular synovitis (PVNS) and tenosynovial giant cell tumor (TGCT). Am J Surg Pathol. 2007 Jun;31(6):970-6.
</p>
<p>
ATP5EP2 (13q12.2) / CSF1 (1p13.3)<br>
COL6A3 (2q37.3) / CSF1 (1p13.3)<br>
CSF1 (1p13.3) / COL6A3 (2q37.3)<br>
CSF1 (1p13.3) / S100A10 (1q21.3)<br>
</div>

<!--
<button class="collapsible">CSF1R (colony stimulating factor 1 receptor) translocation (<a href="https://www.zytovision.com/products/zytolight/z-2202" target="_blank">Zytolight</a>)</button>
<div class="content">
<p>
The ZytoLight ® SPEC CSF1R Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 5q32 harboring the CSF1R gene. Rearrangement of the CSF1R gene was first detected in an acute megakaryoblastic leukemia cell line generating the RBM6-CSF1R fusion gene. This probe is probably not useful in AP.
</p>
</div>
-->

<button class="collapsible">DDIT3 (DNA damage inducible transcript 3) translocation (<a href="https://www.molecular.abbott/int/en/chromosome/12.html" target="_blank">Vysis</a>) and (<a href=".\cap\DDIT3-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for myxoid liposarcoma.
</p>
<p>
Vysis DDIT3 Break Apart FISH Probe Kit and the ZytoLight ® SPEC DDIT3 Dual Color Break Apart Probe are designed to detect translocations involving the chromosomal region 12q13.3 harboring the DDIT3 gene. DDIT3 is consistently rearranged in myxoid liposarcomas.
</p>
<p>
<img src=".\cap\DDIT3partners.jpg" alt="DDIT3 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\LSI-DDIT3-SO_700kb_SGn_663kb_probemap_mw001-orange.png" alt="DDIT3 break apart" width="600"><br>
Vysis Probe
</p>
<p>
<img src=".\cap\DDIT3-BA.jpg" alt="DDIT3 break apart" width="450"><br>
ZytoLight Probe
</p>
</div>

<button class="collapsible">EGFR (epidermal growth factor receptor) gene amplification (<a href=".\cap\EGFR-CEN7.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for brain tumomr typing.
</p>
<p>
The ZytoLight ® SPEC EGFR/CEN 7 Dual Color Probe is designed for the detection of EGFR gene amplification frequently observed in solid neoplasms including non-small-cell lung cancer (NSCLC) and glioblastoma. Overexpression of EGFR has been shown in a number of tumor entities and is associated with poor prognosis. This probe is also used in the diagnostic algorithm of glioma.
</p>
<p>
<img src=".\cap\EGFR-CEN7.png" alt="EGFR amplification" width="450">
</p>
</div>

<button class="collapsible">EWSR1 (EWS RNA binding protein 1) translocation (<a href=".\cap\EWSR1-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for many different sarcomas including angiomatoid fibrous histiocytoma, Clear cell sarcoma of soft parts, desmoplastic small round cell tumor, extraskeletal myoxoid chondrosarcoma, Ewing sarcoma/PNET, myoepithelial tumor, .....
</p>
<p>
The ZytoLight ® SPEC EWSR1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 22q12.2 harboring the EWSR1 gene (Ewing sarcoma breakpoint region 1). There are many fusion partners for the EWSR1 translocation. 
Sanger's Catalogue of Somatic Mutations In Cancer (COSMIC) fusion database provides an updated references of the breakpoints for EWSR1.
</p>
<p>
<img src=".\cap\EWSR1PartnerTum02.jpg" alt="http://atlasgeneticsoncology.org//Genes/EWSR1ID85.html" width="600">
</p>
<p>
<img src=".\cap\EWSR1PartnerTum.jpg" alt="http://atlasgeneticsoncology.org//Genes/EWSR1ID85.html" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\EWSR1-BA.png" alt="EWSR1 break apart" width="450">
</p>
</div>

<button class="collapsible">FUS (FUS RNA binding protein) translocation (<a href="https://www.molecular.abbott/int/en/chromosome/16.html" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
for myxoid liposarcoma.
</p>
<p>
Vysis LSI FUS Break Apart FISH Probe Kit is designed to detect translocations involving the chromosomal region 16p11.2 harboring the FUS gene. FUS gene rearrangements have been shown to be involved in both solid tumors and leukemias, e.g. in over 90% of myxoid liposarcoma.
</p>
<p>
<img src=".\cap\FUSpartners.jpg" alt="FUS partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\LSI_FUS_SGn_505kb_LSI_FUS_SO_275kb_probemap_mw001.png" alt="FUS break apart" width="600">
</p>
</div>

<button class="collapsible">JAZF1 (JAZF zinc finger 1) translocation (<a href=".\cap\JAZF1-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for low grade endometrial stromal sarcoma.
</p>
<p>
The ZytoLight ® SPEC JAZF1 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 7p15.1-p15.2 harboring the JAZF1 gene. In 25-30% of endometrial stromal sarcoma, espectially the low grade ones, the JAZF1 gene is disrupted by another translocation t(6;7) where the first zinc finger domain of JAZF1 is fused to both zinc finger domains of the PHF1 gene at 6p21.32.
</p>
<p>
<img src=".\cap\JAZF1partners.jpg" alt="JAZF1 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\JAZF1-BA.png" alt="JAZF1 break apart" width="450">
</p>
</div>

<button class="collapsible">HER2 (erb-b2 receptor tyrosine kinase 2) gene amplification (<a href="https://www.molecular.abbott/us/en/products/oncology/pathvysion-her-2-dna-probe-kit" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
Please order HER2 DISH for routine breast CA biomarker testing.
</p>
<p>
The PathVysion HER-2 DNA Probe Kit (PathVysion Kit) is designed to detect amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast cancer tissue specimens. We have taken off this test from accreditation. Please order DISH through the desktop little fox for more efficient processing in immuno lab using the automated processor.
</p>
</div>

<button class="collapsible">MAML2 (mastermind like transcriptional coactivator 2) translocation (<a href=".\cap\MAML2-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for mucoepidermoid carcinoma.
</p>
<p>
The ZytoLight ® SPEC MAML2 Dual Color Break Apart Probe is designed to detect the translocation t(11;19)(q21;p13.1) specific for mucoepidermoid carcinomas.
</p>
<p>
<img src=".\cap\MAML2partners.jpg" alt="MAML2 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\MAML2-BA.png" alt="MAML2 break apart" width="450">
</p>
</div>

<button class="collapsible">MDM2 (Murine Double Minute 2) gene amplification  (<a href="https://www.molecular.abbott/int/en/chromosome/12" target="_blank">Vysis</a> and <a href=".\cap\MDM2-CEN12.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for well-differentiated liposarcoma and many others.
</p>
<p>
The Vysis MDM2/CEP 12 FISH Probe Kit and the ZytoLight ® SPEC MDM2/CEN 12 Dual Color Probe are designed for the detection of MDM2 gene amplifications. Well-differentiated liposarcomas (WDLPS) are characterized by the amplification of 12q-derived chromosomal material, harboring the MDM2 oncogene while lipomas show balanced translocations involving 12q13-15. <br><br>
Please note that Vysis probe and Zytolight probe are of different colors:<br><br>
Vysis - MDM2 (red) CEN12 (green)<br>
Zytolight - MDM2 (green) CEN12 (red)<br>
</p>
<p>
<img src=".\cap\LSI-MDM2-SO_209kb_probemap-orange.png" alt="MDM2" width="600"><br>
Vysis Probe
</p>
<p>
<img src=".\cap\MDM2-CEN12.jpg" alt="MDM2 CEN12" width="450"><br>
ZytoLight Probe
</p>
</div>

<button class="collapsible">MET (MET proto-oncogene, receptor tyrosine kinase) gene amplification (<a href=".\cap\MET-CEN7.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for non-small cell lung carcinoma.
</p>
<p>
The ZytoLight ® SPEC MET/CEN 7 Dual Color Probe is designed for the detection of MET gene amplifications found in a variety of human tumors including lung, breast, colorectal, prostate and gastric carcinomas as well as in gliomas,melanomas and some sarcomas. Several inhibitors of the HGF/MET signaling pathway are being studied and developed as potent therapies to inhibit tumor growth.
</p>
<p>
<img src=".\cap\MET-CEN7.png" alt="MET cen7" width="450">
</p>
</div>

<button class="collapsible">MYB (MYB proto-oncogene, transcription factor) translocation (<a href=".\cap\MYB-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for adenoid cystic carcinoma.
</p>
<p>
The ZytoLight ® SPEC MYB Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 6q23.3 harboring the MYB gene. The MYB gene is expressed predominantly in immature progenitor cells of all hematopoietic lineages and is highly expressed in most leukemias and in some solid tumors. Translocations affecting MYB have been detected in T-cell acute lymphoblastic leukemia and adenoid cystic carcinoma. 
</p>
<p>
<img src=".\cap\MYBpartners.jpg" alt="MYB partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\MYB-BA.png" alt="MYB break apart" width="450">
</p>
</div>

<button class="collapsible">MYBL1 (MYB Proto-oncogene Like 1) translocation (<a href="https://empiregenomics.com/product/20768" target="_blank">Empire Genomics</a>)</button>
<div class="content">
<p>
for adenoid cystic carcinoma.
</p>
<p>
For adenoid cystic carcinoma, also consider MYB and NFIB break apart FISH tests. MYBL1 is one of those uncommon partners of NFIB.
</p>
<p>
Chromosome: CHR8: 67474409-67525480<br>
Locus: 8q13.1
</p>
<p>
<img src=".\cap\MYBLpartners.jpg" alt="MYBL1 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
</div>

<button class="collapsible">c-Myc (MYC proto-oncogene, bHLH transcription factor) translocation (<a href="https://www.molecular.abbott/int/en/chromosome/8.html" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
for double-hit, triple-hit diffuse large B-cell lymphoma.
</p>
<p>
Vysis LSI MYC Break Apart Rearrangement Probe Kit is designed to detect translocations involving the chromosomal region 8q24.21 harboring the MYC gene. Translocations involving the MYC gene are considered to be cytogenetic hallmarks for Burkitt Lymphoma but are also found in other types of lymphomas.
</p>
<p>
In high-grade B-cell lymphomas, the presence of MYC aberrations identifies a patient subset with a very poor prognosis, particularly when there is concomitant rearrangement of BCL2 or BCL6, a condition referred to as "double hit” DLBCL. In rare cases translocation involves MYC, BCL2 and BCL6, so called “triple hit”. MYC translocations confer a worse prognosis in patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), both in combination with and without rituximab.
</p>
<p>
<img src=".\cap\MYCpartners.jpg" alt="MYC partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\Vysis-LSI-MYC-Dual-Color-Break-Apart-Rearrangement-Probe_ProbeMap-2.jpg" alt="MYC break apart" width="600">
</p>
</div>

<button class="collapsible">N-myc (MYCN proto-oncogene, bHLH transcription factor) amplification (<a href="https://www.molecular.abbott/int/en/chromosome/2.html" target="_blank">Vysis</a>)</button>
<div class="content">
<p>
for neuroblastoma.
</p>
<p>
Vysis LSI N-MYC SpectrumOrange Probe is designed for the detection of MYCN amplification which represents the most powerful unfavorable prognostic factor for neuroblastoma. Less frequently amplifications are found in retinoblastoma, small cell lung cancer, astrocytoma and other tumors derived from the neuroectoderm. Amplification of the MYCN gene is found in about 25% of primary neuroblastomas and is strongly associated with rapid tumor progression, advanced stages of the disease, and poor prognosis.
</p>
<p>
<img src=".\cap\LSI-N-MYC-SO_200kb_probemap_mw002.png" alt="NMYC amplification" width="600">
</p>
</div>

<button class="collapsible">NFIB (Nuclear Factor I B) translocation (<a href="https://empiregenomics.com/fish-probes/gene/NFIB/break-apart" target="_blank">Empire Genomics</a>)</button>
<div class="content">
<p>
for adenoid cystic carcinoma.
</p>
<p>
The t(6;9)(q22-23;p23-24) translocation in adenoid cystic carcinomas (ACC) of the breast and H&N consistently results in fusions encoding chimeric transcripts predominantly consisting of MYB exon 14 linked to the last coding exon(s) of NFIB. The minimal common part of MYB deleted as the result of fusion was exon 15 including the 3'-UTR, which contains several highly conserved target sites for miR-15a/16 and miR-150 microRNAs. PNAS 2009 106(44):18740-4. 
</p>
<p>
<img src=".\cap\NFIBpartners.jpg" alt="NFIB partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>

</div>

<button class="collapsible">NR4A3 (nuclear receptor subfamily 4 group A member 3) translocation (<a href=".\cap\NR4A3-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for extraskeletal myxoid chondrosarcoma.
</p>
<p>
The ZytoLight ® SPEC NR4A3 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 9q22.33-q31.1. The most frequent reciprocal translocation is t(9;22)(q22.3-q31;q12.2) found in about 70% of extraskeletal myxoid chondrosarcoma generating a EWSR1-NR4A3 fusion gene in which the 3’-terminal part of EWSR1 is replaced by the entire NR4A3 gene. Extraskeletal myxoid chondrosarcoma is histologically characterized by a mixture of cellular and myxoid stromal components, making it difficult to distinguish it from other benign or malignant mesenchymal tumors, especially those with myxoid matrix.
</p>
<p>
<img src=".\cap\NR4A3partners.jpg" alt="NR4A3 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\NR4A3-BA.png" alt="NR4A3 break apart" width="450">
</p>
</div>

<button class="collapsible">NTRK <a href=".\cap\NTRK1-BA.pdf" target="_blank">1</a>, <a href=".\cap\NTRK2-BA.pdf" target="_blank">2</a> & <a href=".\cap\NTRK3-BA.pdf" target="_blank">3</a> (neurotrophic receptor tyrosine kinase 1, 2 & 3) translocations (Zytovision)</button>
<div class="content">
<p>
for pan cancer biomarkers.
</p>
<p>
To detect translocations involving the chromosomal regions 1q23.1 harboring the NTRK1 gene, 9q21.33 harboring the NTRK2 gene, and 15q25.3 harboring the NTRK3 gene, respectively. Tumors presenting NTRK1, NTRK2 and NTRK3 gene fusions can be sensitive to targeted therapies with tyrosine kinase inhibitors. The treatment of patients with NTRK1, 2, or 3 fusion-positive cancers with an NTRK inhibitor, such as the FDA-approved drugs larotrectinib or entrectinib, is associated with high response rates, regardless of NTRK gene, fusion partner, and tumor type.
</p>
<p>
Mixed TRK IHC might be used for preliminary screening.
</p>
<p>
NTRK1 rearrangements were shown to be involved in many different tumor types in which more than 40 different fusion partners have been described, resulting in an activated chimeric NTRK1 gene. 
</p>
<p>
<img src=".\cap\NTRK1partners.jpg" alt="NTRK1 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\NTRK1-BA.jpg" alt="NTRK1 break apart" width="450">
</p>
<p>
NTRK2 is a tyrosine kinase and plays a key role in central and peripheral nervous system development as well as in cell survival. Translocations affecting the NTRK2 gene have been reported in several cancer types, including glioblastomas, pilocytic astrocytomes, H&N squamous cell carcinoma, and lung adenocarcinoma. 
 </p>
<p>
<img src=".\cap\NTRK2partners.jpg" alt="NTRK2 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\NTRK2-BA.jpg" alt="NTRK2 break apart" width="450">
</p>
 <p>
Translocations affecting the NTRK3 gene have been reported in several cancer types, including glioblastomas, Philadelphia chromosome-like acute lymphoblastic leukemia, congenital fibrosarcomas, cellular mesoblastic nephromas, acute myeloid leukemia, radiation-associated thyroid cancer, secretory breast carcinoma, and mammary analog secretory carcinoma of the salivary gland. 
 </p>
 <p>
<img src=".\cap\NTRK3partners.jpg" alt="NTRK3 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\NTRK3-BA.jpg" alt="NTRK3 break apart" width="450">
</p>
</div>

<button class="collapsible">PHF1 (PHD finger protein 1) translocation (<a href=".\cap\PHF1-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for low grade endometrial stroma tumor.
<p>
The ZytoLight ® SPEC PHF1 Dual Color Break Apart Probe is designed for the detection of translocations involving the chromosomal region 6p21.32 harboring the PHF1 gene. Endometrial stromal tumors are the second most common pure mesenchymal tumors of the uterus.
</p>
 <p>
<img src=".\cap\PHF1partners.jpg" alt="PHF1 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
Several rearrangements involving the genes JAZF1, PHF1, or YWHAE have been identified in endometrial stromal tumors.
</p>
<p>
<img src=".\cap\PHF1-BA.png" alt="PHF1 break apart" width="450">
</p>
</div>

<button class="collapsible">PTEN (phosphatase and tensin homolog) deletion probe (<a href=".\cap\PTEN-CEN10.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for brain tumor typing.
</p>
<p>
The ZytoLight ® SPEC PTEN/CEN 10 Dual Color Probe or is designed for the detection of PTEN deletions frequently observed in many tumor types, including renal, melanoma, endometrial, breast, prostate, lung, bladder, and thyroid cancer but also in hematological neoplasms. Deletions affecting the long arm of chromosome 10 have been detected in 30 to 50% of early and advanced stage sporadic melanomas and about 40 to 70% of prostate cancers. This probe can also be used for prognostic evaluation and in the diagnostic algorithm of glioma.
</p>
<p>
<img src=".\cap\PTEN-CEN10.png" alt="PTEN-CEN10" width="450">
</p>
</div>

<button class="collapsible">RET (RET proto-oncogene) translocation (<a href=".\cap\RET-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
potential pan cancer biomarker.
</p>
<p>
The ZytoLight ® SPEC RET Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 10q11.21 harboring the RET gene observed e.g. in lung adenocarcinoma.
</p>
<p>
Since in vitro studies showed transforming activity of KIF5B-RET fusions which could be suppressed by a tyrosine kinase inhibitor, it was assumed that the chimeric oncogene might be a promising molecular target for the treatment of lung cancer. The cut off is set as low as 15% tumor nuclei.
</p>
<p>
<B>RET and 73 translocations/fusion partners</B> <BR> <table><tr><th>Partner Gene</th><th>Chr.</th><th>Location: band (bp)</th><th>Translocation / fusion gene</th><th>Disease</th></tr> <tr><td rowspan="2"><B>TRIM33</B></td><td rowspan="3"><div align="center"><B>1</B></div></td><td rowspan="2" >1p13.2 (114392777)</td><td rowspan="2">t(1;10)(p13;q11) TRIM33/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>RASAL2</B></td><td>1q25.2 (178093729)</td><td>t(1;10)(q25;q11) RASAL2/RET</td><td>Soft tissue sarcoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>EML4</B></td><td rowspan="2"><div align="center"><B>2</B></div></td><td>2p21 (42169338))</td><td>t(2;10)(p21;q11) EML4/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>EML6</B></td><td>2p16.1 (54725012</td><td>t(2;10)(p16;q11) EML6/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>TFG</B></td><td rowspan="2"><div align="center"><B>3</B></div></td><td>3q12.2 (100709331)</td><td>t(3;10)(q12;q11) TFG/RET</td><td>Soft tissues: spindle cell tumors</td></tr> <tr><td><B>TBL1XR1</B></td><td>3q26.32 (177019355)</td><td>t(3;10)(q26;q11) TBL1XR1/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>EPHA5</B></td><td><div align="center"><B>4</B></div></td><td>4q13.1 (65319563)</td><td>t(4;10)(q13;q11) APHA5/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>SQSTM1</B></td><td><div align="center"><B>5</B></div></td><td>5q35.3 (179820842)</td><td>t(5;10)(q35;q11) SQSTM1/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>KIF13A</B></td><td rowspan="7"><div align="center"><B>6</B></div></td><td>6p22.3 (17763693)</td><td>t(6;10)(p22;q11) KIF13A/RET</td><td>Lung: adenocarcinoma</td></tr> <tr><td rowspan="3"><B>TRIM27</B></td><td rowspan="3">6p22.1 (28903002)</td><td rowspan="3">t(6;10)(p22;q11) TRIM27/RET</td><td>Salivary glands: intraductal carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td>Neuro-endocrine tumor: multiple endocrine neoplasia</td></tr> <tr><td><B>TBC1D32</B></td><td>6q22.31 (121079494)</td><td>t(6;10)(q22;q11) TBC1D32/RET</td><td>Lung: adenocarcinoma</td></tr> <tr><td><B>PTPRK</B></td><td>6q22.33 (127968779)</td><td>t(6;10)(q22;q11) PTPRK/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>FGFR1OP</B></td><td>6q27 (166,999,317)</td><td>t(6;10)(q27;q11) FGFR1OP/RET</td><td>Chronic myeloproliferative neoplasm</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>CLIP2</B></td><td rowspan="5"><div align="center"><B>7</B></div></td><td>7q11.23 (74289475)</td><td>t(7;10)(q11;q11) CLIP2/RET</td><td>Soft tissues: spindle mesenchymal neoplasm</td></tr> <tr><td><B>CUX1</B></td><td>7q22.1 (101817602)</td><td>t(7;10)(q22,q11) CUX1/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td rowspan="2"><B>TRIM24</B></td><td rowspan="2">7q33 (138460334)</td><td rowspan="2">t(7;10)(q33;q11) TRIM24/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>TAS2R38</B></td><td>7q34 (141972631)</td><td>t(7;10)(q34;q11) TAS2R38/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td rowspan="2"><B>PCM1</B></td><td rowspan="4"><div align="center"><B>8</B></div></td><td rowspan="2">8p22 (17922857)</td><td rowspan="2">t(8;10)(p22;q11) PCM1/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>RBPMS</B></td><td>8p12 (30384501)</td><td>t(8;10)(p12;q11) RBPMS/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>HOOK3</B></td><td>8p11.21 (42896890)</td><td>t(8;10)(p11;q11) HOOK3/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>FKBP15</B></td><td><div align="center"><B>9</B></div></td><td>9q32 (113165520)</td><td>t(9;10)(q32;q11) FKBP15/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>PRKCQ</B></td><td rowspan="42"><div align="center"><B>10</B></div></td><td><a name="RANGE!C37" id="RANGE!C37">10p15.1 (6427143)</a></td><td>t(10;10)(p15;q11) PRKCQ/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>TAF3&nbsp;</B></td><td>10p14 (7818504)</td><td>t(10;10)(p14;q11) TAF3/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>CCDC3</B></td><td>10p13 (12896625)</td><td>t(10;10)(p13;q11) CCDC3/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>PRPF18</B></td><td>10p13 (13586939)</td><td>t(10;10)(p13;q11) PRPF18/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>FRMD4A</B></td><td>10p13 (13643706)</td><td>t(10;10)(p13;q11) FRMD4A/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td rowspan="2"><B>KIAA1217</B></td><td rowspan="2">10p12.2 (24208791)</td><td rowspan="2">t(10;10)(p12;q11) KIAA1217/RET</td><td>Lung: adenocarcinoma</td></tr> <tr><td>Soft tissues: spindle mesenchymal neoplasm</td></tr> <tr><td><B>ANKRD26</B></td><td>10p12.1 (27004116)&nbsp;</td><td>t(10;10)(p12,q11) ANKRD26/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>ACBD5</B></td><td>10p12.1 (27195214)</td><td>t(10;10)(p12;q11) ACBD5/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>WAC</B></td><td>10p12.1 (28533492)</td><td>t(10;10)(p12;q11) WAC/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>ARHGAP12</B></td><td>10p11.22 (31805398)</td><td>t(10;10)(p11;q11) ARHGAP12/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td rowspan="3"><B>KIF5B</B></td><td rowspan="3">10p11.22 (32009010 )</td><td rowspan="3">t(10;10)(p11;q11) KIF5B/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Skin: melanomas/Spitz tumors</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>PARD3</B></td><td>10p11.22 (34109560)</td><td>t(10;10)(p11;q11) PARD3/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>CCNYL2</B></td><td>10q11.21 (42408174)</td><td>CCNYL2/RET (10q11)</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>RASGEF1A</B></td><td>10q11.21 (43194533)</td><td>RASGEF1A/RET (10q11)</td><td>Breast cancer</td></tr> <tr><td><B>RASSF4</B></td><td>10q11.21 (44959771)</td><td>RASSF4/RET (10q11)</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td rowspan="7"><B>NCOA4</B></td><td rowspan="7">10q11.23 (46005088)</td><td rowspan="7">NCOA4/RET (10q11)</td><td>Breast cancer</td></tr> <tr><td>Colorectal cancer&nbsp;</td></tr> <tr><td>Lung: adenocarcinoma</td></tr> <tr><td>Ovary: Germ cell tumours&nbsp;</td></tr> <tr><td>Salivary glands: intraductal carcinoma</td></tr> <tr><td>Soft tissues: spindle cell tumors</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>PRKG1</B></td><td>10q11.23 (51074474)</td><td>PRKG1/RET (10q11)</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>ANK3</B></td><td>10q21.2 (60026298)</td><td>t(10;10)(q11;q21) ANK3/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>SLC16A9&nbsp;</B></td><td>10q21.2 (59650764)</td><td>t(10;10))(q11;q21) SLC16A9/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td rowspan="3"><B>CCDC6</B></td><td rowspan="3">10q21.2 (59788748)</td><td rowspan="3">t(10;10)(q11;q21) CCDC6/RET</td><td>Colorectal cancer&nbsp;</td></tr> <tr><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>CTNNA3</B></td><td>10q21.3 (65912518)</td><td>t(10;10)(q11;q21) CTNNA3/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>SIRT1</B></td><td>10q21.3 (67884669)</td><td>t(10;10)(q11;q21) SIRT1/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td rowspan="2"><B>RUFY2</B></td><td rowspan="2">10q21.3 (68343518)</td><td rowspan="2">t(10;10)(q11;q21) RUFY2/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>DYDC1</B></td><td>10q23.1 (80336106)</td><td>t(10;10)(q11;q23) DYDC1/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>SORBS1</B></td><td>10q24 (110005804)</td><td>t(10;10)(q11;q24) SORBS1/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>ADD3</B></td><td>10q25.1 (114161608)</td><td>t(10;10)(q11;q25) ADD3/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>CCDC186</B></td><td>10q25.3 (114294824)</td><td>t(10;10)(q11;q25) CCDC186/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>AFAP1L2</B></td><td>10q25.3 (126905409)</td><td>t(10;10)(q11;q25) AFAP1L2/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>DOCK1</B></td><td>10q26.2 (126905409)</td><td>t(10;10)(q11;q26) DOCK1/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>CLRN3</B></td><td>10q26.2 (127877841)</td><td>t(10;10)(q11;q26) CLRN3/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>PPFIBP2</B></td><td rowspan="2"><div align="center"><B>11</B></div></td><td>11p15.4 (7513765)</td><td>t(10;11)(q11;p15) PPFIBP2/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>PICALM</B></td><td>11q14.2 (85957171)</td><td>t(10;11)(q11;q14) PICALM/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>ETV6</B></td><td rowspan="6"><div align="center"><B>12</B></div></td><td>12p13.2 (11649854)</td><td>t(10;12)(q11;p13) ETV6/RET</td><td>Salivary glands: mammary analog secretory carcinoma</td></tr> <tr><td rowspan="3"><B>ERC1</B></td><td rowspan="3">12q13.33 (991208 )</td><td rowspan="3">t(10;12)(q11;q13) ERC1/RET</td><td>Breast cancer</td></tr> <tr><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>ANKS1B</B></td><td>12q23.1 (98743974)</td><td>t(10;12)(q11;q23) ANKS1B/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>CLIP1</B></td><td>12q24.31 (122271434)</td><td>t(10;12)(q11;q24) CLIP1/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>TSSK4</B></td><td rowspan="5"><div align="center"><B>14</B></div></td><td>14q12 (24205720)</td><td>t(10;14)(q11;q12) TSSK4/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>KTN1</B></td><td>14q22.3 (55580207)</td><td>t(10;14)(q11;q22) KTN1/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>CCDC88C</B></td><td>14q32.11 (91271323)</td><td>t(10;14)(q11;q32) CCDC88C/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td rowspan="2"><B>GOLGA5</B></td><td rowspan="2">14q32.12 (92794231)</td><td rowspan="2">t(10;14)(q11;q32) GOLGA5/RET</td><td>Skin: melanomas/Spitz tumors</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>MYO5C</B></td><td rowspan="2"><div align="center"><B>15</B></div></td><td>15q21.2 (52192318)</td><td>t(10;15)(q11;q21) MYO5C/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td><B>AKAP13</B></td><td>15q25.3 (85380616)</td><td>t(10;15)(q11;q25) AKAP13/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td rowspan="2"><B>MYH10</B></td><td rowspan="6"><div align="center"><B>17</B></div></td><td rowspan="2">17p13.1 (8474205)</td><td rowspan="2">t(10;17)(q11;p13) MYH10/RET</td><td>Soft tissues: Infantile myofibromatosis</td></tr> <tr><td>Soft tissues: spindle mesenchymal neoplasm</td></tr> <tr><td><B>MYH13</B></td><td>17p13.1 (10300866)</td><td>t(10;17)(q11;p13) MYH13/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>MPRIP</B></td><td>17p11.2 (17042760)</td><td>t(10;17)(q11;p11) MPRIP/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td rowspan="2"><B>PRKAR1A</B></td><td rowspan="2">17q24.2 (68512379)</td><td rowspan="2">t(10;17)(q11;q24) PRKAR1A/RET</td><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Neuro-endocrine tumor</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td rowspan="3"><B>RELCH (KIAA1468)</B></td><td rowspan="3"><div align="center"><B>18</B></div></td><td rowspan="3">18q21.33 (62187291)</td><td rowspan="3">t(10;18)(q11;q21) KIAA1468/RET</td><td>Lung: adenocarcinoma</td></tr> <tr><td>Lung: non-small cell lung carcinoma</td></tr> <tr><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>LSM14A</B></td><td><div align="center"><B>19</B></div></td><td>19q13.11 (34172447)</td><td>t(10;19)(q11;q13) LSM14A/RET</td><td>Lung: adenocarcinoma</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>RRBP1</B></td><td><div align="center"><B>20</B></div></td><td>20p12.1 (17613678)</td><td>t(10;20)(q11;p12) RRBP1/RET</td><td>Colorectal cancer&nbsp;</td></tr> <tr><td></td><td><div align="center"></div></td><td></td><td></td><td></td></tr> <tr><td><B>BCR</B></td><td rowspan="3"><div align="center"><B>22</B></div></td><td>22q11.23 (23180365)</td><td>t(10;22)(q11;q11) BCR/RET&nbsp;</td><td>Chronic myeloproliferative neoplasm</td></tr> <tr><td><B>SPECC1L</B></td><td>22q11.23 (24270817)</td><td>t(10;22)(q11;q11) SPECC1L/RET</td><td>Thyroid: papillary thyroid carcinoma</td></tr> <tr><td><B>TIMP3</B></td><td>22q12.3 (32800816)</td><td>t(10;22)(q11&nbsp;;q12) TIMP3/RET</td><td>Soft tissues: Inflammatory myofibroblastic tumor</td></tr></table></TD></TR>
</TABLE>
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\RET-BA.png" alt="RET break apart" width="450">
</p>
</div>

<button class="collapsible">ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) translocation  (<a href="https://www.molecularcatalog.abbott/int/en/Vysis-ROS1-Break-Apart-FISH-Probe-Kit" target="_blank">Vysis</a> and <a href=".\cap\ROS1-BA.pdf" target="_blank">Zytovision</a>)</button> 
<div class="content">
<p>
for non-small cell lung carcinoma (CAP accredited test).
</p>
<p>
The Vysis ROS1 Break Apart FISH Probe Kit or the ZytoLight ® SPEC ROS1 Dual Color Break Apart Probe is designed to detect ROS1 gene rearrangements at 6q22.1 involving the receptor tyrosine kinase (ROS1) gene. Rearrangement of the ROS1 gene occurs in:</p>

- 0.2%-2.4% of Colorectal Cancers (CRC),<br>
- 1%-2% of Non-Small Cell Lung Cancer (NSCLC) leading to its oncogenic activation<br>
- Gastric Adenocarcinoma<br>
- Various types of melanoma, inflammatory myofibroblastic tumor, and angiosarcoma<br>
- Epithelioid hemangioendothelioma.<br>
</p>
<p>
<img src=".\cap\ROS1-review.png" alt="ROS1 review" width="600"><br>
a) ROS1 fusions have been identified in several cancer types that occur in adults and/or children (shown on a body map). Upstream gene partners of ROS1 fusions found in specific cancer types are listed. Among these, CLIP1, KIF21A, ST13, TRIM24 and SLC6A17 (blue font) were identified within the cBioPortal database but have not been reported in peer-reviewed publications. In terms of the absolute number of patients affected, ROS1 fusions are most often found in non-small-cell lung cancers (NSCLCs) given the substantial global burden of this disease relative to that of other malignancies. According to data from the cBioPortal, 78% of patients found to have a ROS1 fusion in their cancer had lung adenocarcinoma, with other cancers accounting for the remaining 22%. The prevalence of ROS1 fusions is higher among certain rare cancers such as Spitzoid neoplasms and inflammatory myofibroblastic tumours (IMTs), which affect a smaller total number of patients as compared with NSCLC. The reported prevalence of ROS1 fusions is indicated for certain cancers in parentheses in the Figure. b) ROS1 fusion partner frequencies in ROS1-rearranged NSCLCs, adult glioblastomas, IMTs and Spitzoid neoplasms are shown in circular plots (percentages shown). Large-cohort studies are lacking for other cancer types, and frequency data are thus unavailable. See Supplementary Table 1 for data on median or aggregate frequencies for each cancer type. c) The locations of four major intronic breakpoints (within introns 31, 33, 34 or 35) that generate ROS1 fusions are indicated by arrows in the upper panel. The domain organization of recurrent ROS1 fusions in NSCLC, glioblastoma, IMT and Spitz tumours is shown in the lower panel. An intact ROS1 tyrosine kinase domain (KD) and the C-terminal domain (corresponding to exons 36–43) are included in all fusions. However, ROS1 fusions can also include a portion of the last fibronectin type III (FN) motif repeat (exon 32), the transmembrane (TM) domain (exon 33) and/or a portion of the juxtamembrane domain (exons 34 and 35) of ROS1; retention of portions of these domains does not seem to affect oncogenicity. The majority of NSCLC-associated ROS1 fusion partners lack dimerization motifs, suggesting that canonical dimerization might not be required for oncogenic activation. Distinct from the native receptor, ROS1 fusions might be activated simply by conformational changes induced by the removal of most of the extracellular domain and redirection of this activity to novel subcellular locations. d) The subcellular localizations of select ROS1 fusion proteins are depicted. CC, coiled-coil domain; FERM, band 4.1 homology and ezrin–radixin–moesin domain; PDZ, PSD95, Dlg1 and ZO-1 domain. (Drilon et al, 2021, Nature Reviews Clinical Oncology (18), pp.35–55.)
</p>
<p>
<img src=".\cap\ROS1-FISH.jpg" alt="ROS1 break apart" width="600"><br>
See also "IASLC Atlas of ALK adn ROS1 testing in lung cancer 2e".
</p>
 <p>
<img src=".\cap\ROS1partners.jpg" alt="ROS1 partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\ROS1_BA_FISH_CE_ProbeMap_557kb_317kb_SOrange_and_SGreen.jpg" alt="ROS1 break apart" width="600"><br>
Vysis Probe
</p>
<p>
<img src=".\cap\ROS1-BA.jpg" alt="ROS1 break apart" width="450"><br>
ZytoLight Probe
</p>
</div>

<button class="collapsible">SS18 (SS18 subunit of BAF chromatin remodeling complex) translocation (<a href=".\cap\SS18-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for synovial sarcoma.
</p>
<p>
The ZytoLight ® SPEC SS18 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region 18q11.2 harboring the SS18 gene. Translocations involving the region 18q11.2 are found in over 90% of synovial sarcoma. 
</p>
<p>
<img src=".\cap\SS18partners.jpg" alt="SS18 fusion partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\SS18-BA.png" alt="SS18 break apart" width="450">
</p>
</div>

<button class="collapsible">TFE3 (transcription factor binding to IGHM enhancer 3) translocation (<a href=".\cap\TFE3-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for papillary RCC and alveolar soft part sarcoma.
</p>
<p>
The ZytoLight ® SPEC TFE3 Dual Color Break Apart Probe is designed to detect translocations involving the chromosomal region Xp11.23 harboring the TFE3 gene. Translocations involving the chromosomal region Xp11.2 are frequently detected in some forms of renal cell carcinomas (e.g. papillary RCC), and in alveolar soft part sarcoma.
</p>
<p>
<img src=".\cap\TFE3partners.jpg" alt="TFE3 fusion partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\TFE3-BA.png" alt="TFE3 break apart" width="450">
</p>
</div>

<button class="collapsible">USP6 (ubiquitin specific peptidase 6) translocation (<a href=".\cap\USP6-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for nodular fasciitis and primary ABC.
</p>
<p>
The ZytoLight ® SPEC USP6 Dual Color Break Apart Probe is designed to detect translocations involving the USP6 gene, at chromosome location, 17p13.2. Translocations affecting USP6 have been found in primary aneurysmal bone cysts (ABC) and nodular fasciitis (NF).
</p>
<p>
<img src=".\cap\USP6partners.jpg" alt="USP6 fusion partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\USP6-BA.png" alt="USP6 break apart" width="450">
</p>
</div>

<button class="collapsible">YWHAE translocation (<a href=".\cap\YWHAE-BA.pdf" target="_blank">Zytovision</a>)</button>
<div class="content">
<p>
for high-grade endometrial stromal sarcoma.
</p>
<p>
The ZytoLight ® SPEC YWHAE Dual Color Break Apart Probe is designed to detect rearrangements involving the chromosomal region 17p13.3 harboring the YWHAE gene. Altered expression of 14-3-3 family proteins is associated with development and progression of cancer. The fusion between YWHAE and one of the FAM22 family members (FAM22A or FAM22B) caused by a t(10;17)(q22;p13) has been identified in high-grade endometrial stromal sarcoma (ESS) as well as in clear cell sarcoma of the kidney (CCSK).
</p>
<p>
Official Full Name: YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon <br>
Locus: 17p13.3
</p>
<p>
<img src=".\cap\YWHAEpartners.jpg" alt="YWHAE fusion partners" width="600">
adapted from "Atlas of Genetics and Cytogenetics in Oncology and Haematology"
</p>
<p>
<img src=".\cap\YWHAE-BA.png" alt="YWHAE break apart" width="450">
</p>
</div>

<script>
var coll = document.getElementsByClassName("collapsible");
var i;

for (i = 0; i < coll.length; i++) {
  coll[i].addEventListener("click", function() {
    this.classList.toggle("active");
    var content = this.nextElementSibling;
    if (content.style.maxHeight){
      content.style.maxHeight = null;
    } else {
      content.style.maxHeight = content.scrollHeight + "px";
    } 
  });
}
</script>
 </div>
 
<br>
<div id = "footer">
Last upated on 01-Jan-2021.<br><br>
Gene names commonly used in the laboratory and the official names by <a href="https://https://www.genenames.org/" target="_blank">HGNC</a> are provided.<br> 
The html form and cascade style sheet were created on <a href="https://www.phpform.org" target="_blank">pForm</a>,<br>
with references to Javascripts and codes published in <a href="https://www.w3schools.com/" target="_blank">W3 School</a> and <a href="https://stackoverflow.com/" target="_blank">StackOverflow</a><br>
and image modified from <a href="https://icons8.com" target="_blank">Icons8</a>.<br> Information of each of the probe was adapted from the respective manufacturer's website.
<br>
<br>
<br>
Anatomical Pathology Division, Queen Mary Hospital, Hong Kong.
</div>
</div>
</div>
<img id="bottom" src="bottom.png" alt="">


</body>
</html>
